Conclusion
In these cases, we would like to emphasize that the combination of
lamotrigine and valproic acid to control seizures can cause
life-threatening skin reactions such as SJS/TEN and DRESS syndrome. the
physicians should be alert and have to be aware of that when prescribing
antiepileptic drugs.
References
- A.WArshavsky, A.Eilam, and R.Gilad. Lamotrigene as a monotherapy in
clinical practice: efficacy of various dosages in epilepsy. Brain and
Behaviour. Vol6. N°3. Article e00419.
- J. R. Calabrese, J. R. Sullivan, C. L. Bowden et al., “Rash in
multicenter trials of lamotrigine in mood disorders: clinical
relevance and management,” Journal of Clinical Psychiatry, vol. 63,
no. 11, pp. 1012–1019, 2002.
- O. Egunsola, I. Choonara, and H. M. Sammons, “Safety of lamotrigine
in paediatrics: a systematic review,” BMJ Open, vol. 5, no. 6,
article e007711, 2015.
- Noguera-Morel L, Hernandez-Martin A, Torrelo A. Cutaneous drug
reactions in the pediatric population. Pediatr Clin North Am 2014; 61:
403-26.
- Gomes E, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et
al. Drug hypersentivity in children : report from the pediatric Task
Force of the EAACI Drug Allergy Interest Group. Allergy 2016; 71:
149-61.
- Teo YX, Walsh SA. Severe drug reactions. Clin Med 2016; 16: 79-83.
- Hoetzenecker. W, Nägeli MM, Mehra ET, Jensen AN, Saulite I,
Schimid-Grendelmeier P, et al. Adverse cutaneous drug eruptions :
current understanding. Semin Immunopathol 2016 ; 38 : 75-86.
- Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical
perspectives. J Am Acad Dermatol 2013;68:693.e1-693.e14. quiz 706-708.
- Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al.
The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.
- Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, et al.
Successful Intravenous Immunoglobulin Treatment in Pediatric Severe
DRESS Syndrome. J Allergy Clin Immunol Pract. août 2018;6(4):1238‑42.
- Yapici AK, Fidanci MK, Kilic S, Balamtekin N, Mutluay Arslan M, Yavuz
ST, et al. Stevens-Johnson Syndrome triggered by a combination of
clobazam, lamotrigine and valproic acid in a 7-year-old child. Ann
Burns Fire Disasters. 30 sept 2014;27(3):121‑5.
- Mockenhaupt M, Viboud C, Dunant A et al.: Stevens-Johnson syndrome and
toxic epidermal necrolysis: assessment of medication risks with
emphasis on recently marketed drugs. The EuroSCARstudy. J Invest
Dermatol, 128: 35-44, 2008.
- French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome:
our current understanding. Allergol Int, 55: 9-16, 2006.
- Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson
Syndrome - PubMed [Internet]. [cité 25 févr 2021]. Disponible
sur:https://pubmed.ncbi.nlm.nih.gov/30228819/
- W. Lu and J. P. Uetrecht, “Possible bioactivation pathways of
lamotrigine,” Drug Metabolism and Disposition, vol. 35, no. 7, pp.
1050–1056, 2007.
- M. Lalic, J. Cvejic, J. Popovic et al., “Lamotrigine and valproate
pharmacokinetics interactions in epileptic patients,”European Journal
of Drug Metabolism and Pharmacokinetics, vol. 34, no. 2, pp. 93–99,
2009
- A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G.
Dickinson, and J. O. Miners, “In vitro characterization of
lamotrigine N2-glucuronidation and the lamotrigine-valproic acid
interaction,” Drug Metabolism and Disposition, vol. 34, no. 6, pp.
1055–1062, 2006.
- L. W. Wormhoudt, J. N. Commandeur, and N. P. Vermeulen, “Genetic
polymorphisms of human N-acetyltransferase, cytochrome P450,
glutathione S-transferase, and epoxide hydrolase enzymes: relevance to
xenobiotic metabolism and toxicity,” Critical Reviews in Toxicology,
vol. 29, no. 1, pp. 59–124, 1999.
- O. Spiegelstein, D. L. Kroetz, R. H. Levy et al., “Structure activity
relationship of human microsomal epoxide hydrolase inhibition by amide
and acid analogues of valproic acid,” Pharmaceutical Research, vol.
17, no. 2, pp. 216–221, 2000.
- M. Rosa, P. Bonnaillie, and H. Chanteux, “Prediction of drug–drug
interactions with carbamazepine-10,11-epoxide using a new in vitro
assay for epoxide hydrolase inhibition,” Xenobiotica, vol. 46, no.
12, pp. 1076–1084, 2016.
- D. Diki´c, D. Jutri´c, and K. Dominko, “)e dual nature of the
antiepileptic drug valproic acid, with possible beneficial effects in
Alzheimer’s disease,” SEEMEDJ, vol. 1, no. 1, pp. 74–89, 2017.
- X. Wang, B. Iv, H. Wang et al., “Lamotrigine-induced severe cutaneous
adverse reaction: update data from 1999–2014,” Journal of Clinical
Neuroscience, vol. 22, no. 6, pp. 1005–1011, 2015.
- K. Maduemem, A. Vatca, T. O’Neill, and D. Buckley, “Stevens– Johnson
syndrome induced by combination of lamotrigine and valproic acid in a
9-year-old boy,” Irish Medical Journal, vol. 110, no. 6, p. 586,
2017.
- Dibek Misirlioglu E, Guvenir H, Bahceci S, Haktanir Abul M, Can D,
Usta Guc BE, et al. Severe Cutaneous Adverse Drug Reactions in
Pediatric Patients: A Multicenter Study. J Allergy Clin Immunol Pract.
juin 2017;5(3):757‑63.